4-(7H-purin-6-ylsulfanyl)but-3-en-2-one | 76664-26-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 英文名称: 4-(7H-purin-6-ylsulfanyl)but-3-en-2-one
• CAS: 76664-26-1
• 化学式: C₉H₈N₄OS
• 分子量: 220.25
• InChiKey: UTZQOKLQPPYAKV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  96.8
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• Treatment of cancer with a combination of radiation, cerium oxide nanoparticles, and a chemotherapeutic agent
  申请人：BioCurity Pharmaceuticals Inc.

  公开号：US11389536B2

  公开（公告）日：2022-07-19

  The present invention is directed to methods for the treatment of cancer with a combination of radiation, cerium oxide nanoparticles and at least one chemotherapeutic agent. Cerium oxide nanoparticles (CONPs) are nanometer-sized crystals of cerium oxide, typically ranging between about one nanometer to about 20 nanometers in longest dimension. The present methods use cerium oxide nanoparticles to enhance radiation-induced and chemotherapy-induced cancer cell death and also reduce the toxicity associated with radiation therapy and chemotherapy.

  本发明涉及用辐射、氧化铈纳米粒子和至少一种化疗剂组合治疗癌症的方法。氧化铈纳米粒子（CONPs）是纳米尺寸的氧化铈晶体，其最长尺寸通常在约 1 纳米到约 20 纳米之间。本方法使用氧化铈纳米粒子来增强辐射诱导和化疗诱导的癌细胞死亡，同时降低与放疗和化疗相关的毒性。
• ANTIVIRAL AGENTS AND METHODS OF USE
  申请人：Striker T. Robert

  公开号：US20050119284A1

  公开（公告）日：2005-06-02

  The present invention provides therapeutic methods of inhibiting RNA viruses based on the newly-discovered anti-viral activity of cis or trans-6-(2-acetylvinylthio)purine (cis-AVTP) or (trans-AVTP). RNA viruses inhibited by the methods include flaviviruses, namely hepatitis C virus (HCV) and bovine diarrhea virus (BVDV).

  本发明基于新发现的顺式或反式-6-(2-乙酰乙烯硫基)嘌呤（顺式-AVTP）或（反式-AVTP）的抗病毒活性，提供了抑制 RNA 病毒的治疗方法。这些方法可抑制的 RNA 病毒包括黄病毒，即丙型肝炎病毒（HCV）和牛腹泻病毒（BVDV）。
• TREATMENT OF CANCER WITH A COMBINATION OF RADIATION, CERIUM OXIDE NANOPARTICLES, AND A CHEMOTHERAPEUTIC AGENT
  申请人：Biocurity Holdings, Inc.

  公开号：EP3169312A1

  公开（公告）日：2017-05-24
• Glutathione-activated anti-tumor prodrugs of 6-mercaptopurine and 6-thioguanine
  申请人：——

  公开号：US20040023994A1

  公开（公告）日：2004-02-05

  The present invention relates to a method for treating a tumor in a tissue of a human or non-human animal, the tumor having an elevated level of glutathione relative to the tissue, the method comprising the steps of administering to the animal a prodrug comprising a thiopurine having a sulfur heteroatom conjugated to an alpha-, beta-unsaturated carbonyl moiety, in combination with a pharmaceutically acceptable carrier, the moiety comprising a double bond having an alpha end and a beta end, the beta end being accessible to glutathione in an addition-elimination reaction, the prodrug lacking an ionizable carboxylic acid group; and observing a reduction in growth of the tumor.
• [EN] TREATMENT OF CANCER WITH A COMBINATION OF RADIATION, CERIUM OXIDE NANOPARTICLES, AND A CHEMOTHERAPEUTIC AGENT<br/>[FR] TRAITEMENT DU CANCER ASSOCIANT UN RAYONNEMENT, DES NANOPARTICULES D'OXYDE DE CÉRIUM ET UN AGENT CHIMIOTHÉRAPEUTIQUE
  申请人：BAKER CHERYL

  公开号：WO2016011328A1

  公开（公告）日：2016-01-21

  The present invention is directed to methods for the treatment of cancer with a combination of radiation, cerium oxide nanoparticles and at least one chemotherapeutic agent. Cerium oxide nanoparticles (CONPs) are nanometer-sized crystals of cerium oxide, typically ranging between about one nanometer to about 20 nanometers in longest dimension. The present methods use cerium oxide nanoparticles to enhance radiation-induced and chemotherapy-induced cancer cell death and also reduce the toxicity associated with radiation therapy and chemotherapy